Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective
Charis Wong,Maria Stavrou,Elizabeth Elliott,Jenna M Gregory,Nigel Leigh,Ashwin A Pinto,Timothy L Williams,Jeremy Chataway,Robert Swingler,Mahesh K B Parmar,Nigel Stallard,Christopher J Weir,Richard A Parker,Amina Chaouch,Hisham Hamdalla,John Ealing,George Gorrie,Ian Morrison,Callum Duncan,Peter Connelly,Francisco Javier Carod-Artal,Richard Davenport,Pablo Garcia Reitboeck,Aleksandar Radunovic,Venkataramanan Srinivasan,Jenny Preston,Arpan R Mehta,Danielle Leighton,Stella Glasmacher,Emily Beswick,Jill Williamson,Amy Stenson,Christine Weaver,Judith Newton,Dawn Lyle,Rachel Dakin,Malcolm Macleod,Suvankar Pal,Siddharthan Chandran
DOI: https://doi.org/10.1093/braincomms/fcab242
2021-10-01
Brain Communications
Abstract:Abstract Amyotrophic lateral sclerosis is a progressive and devastating neurodegenerative disease. Despite decades of clinical trials, effective disease-modifying drugs remain scarce. To understand the challenges of trial design and delivery, we performed a systematic review of Phase II, Phase II/III and Phase III amyotrophic lateral sclerosis clinical drug trials on trial registries and PubMed between 2008 and 2019. We identified 125 trials, investigating 76 drugs and recruiting more than 15 000 people with amyotrophic lateral sclerosis. About 90% of trials used traditional fixed designs. The limitations in understanding of disease biology, outcome measures, resources and barriers to trial participation in a rapidly progressive, disabling and heterogenous disease hindered timely and definitive evaluation of drugs in two-arm trials. Innovative trial designs, especially adaptive platform trials may offer significant efficiency gains to this end. We propose a flexible and scalable multi-arm, multi-stage trial platform where opportunities to participate in a clinical trial can become the default for people with amyotrophic lateral sclerosis.